PepGen Inc. (PEPG) Financial Statements (2025 and earlier)

Company Profile

Business Address 1 MARINA PARK DRIVE, SUITE 900
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:120,200,000110,400,000181,752,000
Cash and cash equivalent49,421,00080,774,000181,752,000
Short-term investments70,770,00029,633,000 
Other undisclosed cash, cash equivalents, and short-term investments9,000(7,000) 
Receivables   58,000
Deferred costs  4,100,0004,100,000
Other undisclosed current assets3,561,000(1,822,000)173,000
Total current assets:123,761,000112,678,000186,083,000
Noncurrent Assets
Operating lease, right-of-use asset21,432,00023,620,00026,549,000
Property, plant and equipment3,716,0004,764,0003,335,000
Restricted cash and investments1,548,000  
Other noncurrent assets426,0001,990,0001,473,000
Total noncurrent assets:27,122,00030,374,00031,357,000
TOTAL ASSETS:150,883,000143,052,000217,440,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,602,00014,527,00013,275,000
Accounts payable1,752,0001,005,0001,362,000
Accrued liabilities11,850,00013,522,00011,913,000
Other undisclosed current liabilities3,094,0003,004,0005,553,000
Total current liabilities:16,696,00017,531,00018,828,000
Noncurrent Liabilities
Liabilities, other than long-term debt15,567,00017,100,00018,981,000
Operating lease, liability15,567,00017,100,00018,981,000
Total noncurrent liabilities:15,567,00017,100,00018,981,000
Total liabilities:32,263,00034,631,00037,809,000
Equity
Equity, attributable to parent118,620,000108,421,000179,631,000
Common stock3,0002,0002,000
Additional paid in capital390,057,000289,867,000282,566,000
Accumulated other comprehensive income (loss)23,00034,000(81,000)
Accumulated deficit(271,463,000)(181,482,000)(102,856,000)
Total equity:118,620,000108,421,000179,631,000
TOTAL LIABILITIES AND EQUITY:150,883,000143,052,000217,440,000

Income Statement (P&L) (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
Operating expenses(97,739,000)(84,766,000)(68,301,000)
Operating loss:(97,739,000)(84,766,000)(68,301,000)
Nonoperating income7,141,0006,213,0002,903,000
Investment income, nonoperating7,142,0006,400,0002,793,000
Loss from continuing operations before income taxes:(90,598,000)(78,553,000)(65,398,000)
Income tax expense (benefit) 617,000(73,000)(3,706,000)
Other undisclosed income from continuing operations   
Net loss available to common stockholders, diluted:(89,981,000)(78,626,000)(69,104,000)

Comprehensive Income (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
Net loss:(89,981,000)(78,626,000)(69,104,000)
Comprehensive loss:(89,981,000)(78,626,000)(69,104,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(11,000)115,000(98,000)
Comprehensive loss, net of tax, attributable to parent:(89,992,000)(78,511,000)(69,202,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: